Suspended worldwide 2007-2008 after BART trial showed increased mortality vs other antifibrinolytics; reintroduced with restrictions in EU (2012) and Canada; remains unavailable in the US
Failed Loading the evidence…
Locate reported clinical setbacks and repeated preclinical work without linked human trials. These are starting points for scrutiny, not ranked investment opportunities.
Classified failures with attached source descriptions. This includes clinical failures and post-market reversals; it does not imply every trial or indication failed.
Suspended worldwide 2007-2008 after BART trial showed increased mortality vs other antifibrinolytics; reintroduced with restrictions in EU (2012) and Canada; remains unavailable in the US
FailedWithdrawn/banned in most countries due to bromism (neurotoxicity), addiction, and overdose/suicide risk (ChEMBL withdrawn_flag = true)
FailedMarketing authorisation suspended in France (Feb 2011) and across the EU by EMA (2011) due to serious/fatal neurological (seizures, status epilepticus) and cardiac (arrhythmia, cardiac arrest) toxicity. ChEMBL withdrawn_flag set.
FailedWithdrawn (US 2002); WHO Primary Prevention trial showed ~25% increase in all-cause mortality (excess non-cardiovascular deaths, cancer, gallstones, pancreatitis)
FailedEMA/PRAC-endorsed withdrawal of marketing authorisation across EU in 2018 due to risk of acute liver failure (hepatotoxicity)
FailedEMA marketing authorisation withdrawn 11 Feb 2020 and global LEO withdrawal; increased skin malignancy (SCC) risk outweighs benefit (PRAC April 2020)
Failed1989-90 eosinophilia-myalgia syndrome (EMS) outbreak: >1,500 cases and 37 deaths traced to contaminated Showa Denko batches; FDA nationwide recall/ban 1990 (returned ~2005). ChEMBL withdrawn_flag set.
FailedWithdrawn (ChEMBL withdrawn_flag = true); hepatotoxicity and androgenic adverse effects; banned/controlled substance
FailedWithdrawn from major markets (e.g. US) due to QT prolongation / torsades-de-pointes risk and marked HDL-cholesterol lowering. ChEMBL withdrawn_flag set.
FailedWithdrawn from all markets Oct 2011 by Eli Lilly after PROWESS-SHOCK showed no survival benefit; bleeding risk
FailedASCEND-HF (2011, n=7141) showed no benefit on death/HF rehospitalization; use collapsed and Janssen discontinued manufacturing (2018)
FailedWithdrawn worldwide 30 Sept 2004 (Merck voluntary) due to increased myocardial infarction/stroke risk (APPROVe/VIGOR)
FailedEMA suspended EU marketing authorisation (Sept 2010) for increased cardiovascular (ischaemic) risk; FDA imposed a boxed warning and restricted-access REMS program (later eased in 2013 and removed 2015). ChEMBL withdrawn_flag set.
FailedHepatotoxicity; withdrawn from markets (e.g., Australia, France); Loprinzi NEJM 1999 RCT found no benefit for lymphoedema and a case of hepatotoxicity; ChEMBL withdrawn_flag true
FailedWithdrawn from US market (2000) and Canada (2003) due to agranulocytosis (also vasculitis, leukoencephalopathy)
FailedSelected agents with repeated rodent studies. Check each dossier for trial-link completeness and extraction context.
Drug · 4 reported studies
No linked human trial in this dataset.
Predominantly beneficial preclinical findings reportedDrug · 3 reported studies
No linked human trial in this dataset.
Predominantly beneficial preclinical findings reportedNo ChEMBL mechanism-of-action table record; flagged in ChEMBL as a chemical probe (chemical_probe=1) with no assigned max_phase. Reported in the literature as a GSK-3 inhibitor; not asserted from ChEMBL here. · 3 reported studies
No linked human trial in this dataset.
Predominantly beneficial preclinical findings reportedHormone · 3 reported studies
No linked human trial in this dataset.
Predominantly beneficial preclinical findings reportedOther · 2 reported studies
No linked human trial in this dataset.
Predominantly beneficial preclinical findings reportedNo ChEMBL mechanism_of_action record for clodronic acid. Clinically a non-nitrogenous bisphosphonate (ATC M05BA02); in the source study the liposomal formulation is used to deplete phagocytic macrophages. Co-agent rolipram resolved separately as CHEMBL63 (phosphodiesterase 4 inhibitor, target CHEMBL2093863, max_phase 2). · 2 reported studies
No linked human trial in this dataset.
Predominantly beneficial preclinical findings reportedDrug · 2 reported studies
No linked human trial in this dataset.
Predominantly beneficial preclinical findings reportedBroad-spectrum matrix metalloproteinase (MMP) inhibitor; no ChEMBL mechanism record. · 2 reported studies
No linked human trial in this dataset.
Predominantly beneficial preclinical findings reportedNo ChEMBL mechanism-of-action table record. Endogenous adrenal steroid (5-androstene-3beta,17beta-diol), natural product flag true, max_phase -1 (clinical phase unknown in ChEMBL). · 2 reported studies
No linked human trial in this dataset.
Predominantly beneficial preclinical findings reportedPARTIAL: spermine matched in ChEMBL as a natural polyamine (max_phase 0.5, therapeutic_flag false); get_mechanism returned 0 records, an explicit negative result. Ruthenium red returned 0 ChEMBL hits; its reported activity as a mitochondrial calcium uniporter inhibitor comes from the source literature, not ChEMBL. ClinicalTrials.gov searched for both agents: all hits were term collisions (SMS text-messaging and small-mobile-stem-cell studies) and were rejected, so zero trials is a deliberate filtered decision, not an omission. · 2 reported studies
No linked human trial in this dataset.
Predominantly beneficial preclinical findings reportedBET bromodomain (BRD4/BRD2/BRD3) inhibitor. ChEMBL flags this molecule as a chemical probe (chemical_probe=1) with max_phase null and no entry in the ChEMBL mechanism table, so moa_list is empty; the BET-inhibitor assignment is from the primary literature and probe annotation, not from ChEMBL MoA records. · 2 reported studies
No linked human trial in this dataset.
Predominantly beneficial preclinical findings reportedDrug · 11 reported studies
No linked human trial in this dataset.
Preclinical evidence requires assessmentDrug · 2 reported studies
No linked human trial in this dataset.
Preclinical evidence requires assessmentDrug · 2 reported studies
No linked human trial in this dataset.
Preclinical evidence requires assessment